Phil is an experienced technical director with a track record of holding successful leadership roles in advanced cell and gene therapy process development, operations management, project management, pilot plant and GMP manufacturing facility design, and capital project delivery. Phil has managed projects and programs to deliver safe, high quality and commercially successful outcomes to customers.
With DHC clients, Phil leads facility and engineering design projects, and capacity modeling work. He also addresses capital project business case development and feasibility studies as well as ‘build’ vs. ‘buy’ evaluations.
Phil began his career with Shell Research Ltd. working as a process engineer developing a variety of fermentation-based products.
He then moved to Kvaerner E&C Ltd. where he was responsible for bioprocess equipment and facility design, commissioning and validation for a range of capital projects across Europe including bulk vaccines, monoclonal antibodies, antibiotics and fill-finish facilities. During this time Phil was also seconded to Glaxo Wellcome as a manufacturing strategy analyst to support their global merger into GSK.
Phil joined Foster Wheeler Ltd. as Principal Consultant, Biotechnology, where he led a team of bioprocess engineers designing large scale biopharma facilities in Ireland, Switzerland and Japan.
Phil then moved to California where he worked with Amgen Inc. in a variety of roles, delivering and operating new manufacturing and research facilities for the company across the world. This included leadership of the Clinical Operations engineering team, program direction for a number of corporate improvement programs, capital project delivery in USA, Puerto Rico, Singapore and Ireland, and Director-level responsibility for Amgen’s global investment lifecycle management program.
Just before joining Dark Horse, Phil returned to the UK to join eXmoor Pharma Ltd. As Associate Director, Technology, he was responsible for laboratory management to support and expand viral vector, cell therapy and analytical process development operations safely and efficiently. He led a fast-growing laboratory team focused on cell and gene therapy (CGT) process development and optimization for cost-effective and compliant GMP manufacturing. Phil served on eXmoor’s senior leadership team at a time of rapid company expansion, and consulted for a number of cell and gene therapy companies focused on conceptual design, facility fit and operational readiness activities.